HAE · XBRL financial data

Haemonetics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (HAE's year ends in late March)

In millions of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 30, 2023	Q4 FY24Mar 30, 2024	Q1 FY25Jun 29, 2024	Q2 FY25Sep 28, 2024	Q3 FY25Dec 28, 2024	Q4 FY25Mar 29, 2025	Q1 FY26Jun 28, 2025	Q2 FY26Sep 27, 2025	Q3 FY26Dec 27, 2025	Q4 FY26Mar 28, 2026	Q1 FY27Jun 27, 2026
Revenue from contracts with customers	318	336	343*	336	346	349	331*	321	327	339	346*	339
Cost of goods and services sold	148	158	167*	161	158	155	138*	129	133	137	148*	137
Gross profit	171	178	176*	175	187	194	193*	192	195	202	198*	203
Research and development	13	13	16*	14	17	16	16*	16	15	14	14*	16
Selling, general and administrative	105	112	122*	108	107	106	115*	111	102	109	121*	119
Total operating expenses	135	132	146*	135	136	135	122*	138	136	135	221*	145
Operating income (loss)	35	46	30*	40	52	59	71*	54	58	67	(23)*	57
Interest expense	—	—	year only	—	—	—	year only	—	—	—	year only	—
Other income (expense)	(2)	(2)	(7)*	7	(7)	(9)	(1)*	(9)	(7)	(7)	(5)*	(10)
Income tax expense (benefit)	8	13	3*	8	11	12	13*	11	13	15	(8)*	15
Net income (loss)	25	31	20*	38	34	37	58*	34	39	45	(20)*	33
Earnings per share, basic USD per share	0.49	0.62	0.40*	0.75	0.66	0.75	1.18*	0.71	0.81	0.96	(0.44)*	0.73
Earnings per share, diluted USD per share	0.48	0.61	0.40*	0.74	0.66	0.74	1.17*	0.70	0.81	0.95	(0.43)*	0.72
Weighted average shares, basic millions of shares	51	51	51*	51	51	50	49*	48	48	47	46*	45
Weighted average shares, diluted millions of shares	51	51	51*	52	51	51	49*	48	48	47	46*	46

Fiscal quarters (HAE's year ends in late March)

In millions of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 30, 2023	Q4 FY24Mar 30, 2024	Q1 FY25Jun 29, 2024	Q2 FY25Sep 28, 2024	Q3 FY25Dec 28, 2024	Q4 FY25Mar 29, 2025	Q1 FY26Jun 28, 2025	Q2 FY26Sep 27, 2025	Q3 FY26Dec 27, 2025	Q4 FY26Mar 28, 2026	Q1 FY27Jun 27, 2026
Cash and cash equivalents	351	194	179	344	299	321	307	293	296	363	245	223
Accounts receivable	174	212	207	201	214	212	203	201	207	196	217	216
Inventory	286	304	317	374	382	360	365	361	336	321	306	307
Prepaid and other current assets	55	55	66	59	61	113	60	59	60	63	66	65
Total current assets	866	765	769	979	956	1,006	935	913	900	944	835	811
Property and equipment, net	308	319	311	302	300	286	284	287	292	297	306	304
Right-of-use asset	—	—	55	—	—	—	47	—	—	—	40	—
Goodwill	465	555	565	613	616	605	604	607	606	607	656	657
Total assets	2,011	2,200	2,196	2,541	2,525	2,531	2,451	2,462	2,442	2,491	2,396	2,365
Accounts payable	80	57	73	77	69	63	67	46	62	49	51	56
Current portion of long-term debt	14	14	10	5	5	5	304	304	304	305	5	5
Total current liabilities	264	262	300	260	274	253	578	531	548	540	283	263
Long-term debt	749	857	798	1,218	1,220	1,220	921	921	920	920	1,220	1,169
Lease liability, non-current	—	—	58	—	—	—	50	—	—	—	41	—
Retained earnings	309	340	360	387	369	392	352	356	336	381	279	312
Total stockholders' equity	894	943	960	905	879	907	821	882	849	911	796	837
Total liabilities and equity	2,011	2,200	2,196	2,541	2,525	2,531	2,451	2,462	2,442	2,491	2,396	2,365
Common shares outstanding (cover page) millions of shares	51	51	51	51	50	50	48	48	47	46	45	45

Fiscal quarters (HAE's year ends in late March)

In millions of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 30, 2023	Q4 FY24Mar 30, 2024	Q1 FY25Jun 29, 2024	Q2 FY25Sep 28, 2024	Q3 FY25Dec 28, 2024	Q4 FY25Mar 29, 2025	Q1 FY26Jun 28, 2025	Q2 FY26Sep 27, 2025	Q3 FY26Dec 27, 2025	Q4 FY26Mar 28, 2026	Q1 FY27Jun 27, 2026
Net income (loss)	25	31	20*	38	34	37	58*	34	39	45	(20)*	33
Stock-based compensation	7*	7*	7*	8	7*	8*	7*	9	8*	8*	9*	9
Net cash from operating activities	99*	(1)*	64*	(27)	49*	44*	117*	17	111*	94*	71*	52
Purchases of property and equipment	25*	22*	10*	6	9*	9*	16*	4	5*	6*	18*	8
Net cash from investing activities	(25)*	(269)*	(13)*	(139)	(23)*	(17)*	18*	(33)	(30)*	(29)*	(87)*	(22)
Share repurchases	—	0*	0*	—	—	0*	150*	—	—	0*	100*	—
Repayments of long-term debt	4*	4*	4*	2	0*	2*	2*	2	2*	2*	—	2
Net cash from financing activities	(7)*	109*	(64)*	334	(75)*	1*	(151)*	(2)	(77)*	2*	(101)*	(52)
Net change in cash	65*	(157)*	(15)*	166	(45)*	22*	(14)*	(14)	4*	67*	(118)*	(22)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Haemonetics	223	339	52	45.5M	Q1 FY27 10-QJun 27, 2026
Teleflex	300	570	not reported	42.4M	Q2 FY26 10-QJun 30, 2026
LivaNova	517	391	67*	55.1M	Q2 FY26 10-QJun 30, 2026
Envista Holdings	1,126	731	119*	160.6M	Q2 FY26 10-QJul 3, 2026
Enovis	13	583	75*	57.7M	Q2 FY26 10-QJul 3, 2026
Ufp Technologies	9	174	16*	7.7M	Q2 FY26 10-QJun 30, 2026
Lemaitre Vascular	27	not reported	16*	22.9M	Q2 FY26 10-QJun 30, 2026
AtriCure	168	154	22*	50.9M	Q2 FY26 10-QJun 30, 2026
Dentsply Sirona	239	898	99*	199.4M	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.